Literature DB >> 34772713

Semaglutide for weight loss.

Mo Ojeniran1, Betty Dube1, Allison Paige2, Joey Ton3, Adrienne J Lindblad3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34772713      PMCID： PMC8589135          DOI： 10.46747/cfp.6711842

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  7 in total

1.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Mansoor Husain; Andreas L Birkenfeld; Morten Donsmark; Kathleen Dungan; Freddy G Eliaschewitz; Denise R Franco; Ole K Jeppesen; Ildiko Lingvay; Ofri Mosenzon; Sue D Pedersen; Cees J Tack; Mette Thomsen; Tina Vilsbøll; Mark L Warren; Stephen C Bain
Journal:  N Engl J Med       Date:  2019-06-11       Impact factor: 91.245

2.  Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

Authors:  Patrick M O'Neil; Andreas L Birkenfeld; Barbara McGowan; Ofri Mosenzon; Sue D Pedersen; Sean Wharton; Charlotte Giwercman Carson; Cecilie Heerdegen Jepsen; Maria Kabisch; John P H Wilding
Journal:  Lancet       Date:  2018-08-16       Impact factor: 79.321

3.  Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.

Authors:  Erin R Weeda; Alyssa K Muraoka; Matthew D Brock; Jessica M Cannon
Journal:  Int J Clin Pract       Date:  2021-02-01       Impact factor: 2.503

4.  Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Authors:  Melanie Davies; Louise Færch; Ole K Jeppesen; Arash Pakseresht; Sue D Pedersen; Leigh Perreault; Julio Rosenstock; Iichiro Shimomura; Adie Viljoen; Thomas A Wadden; Ildiko Lingvay
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

5.  Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Authors:  Thomas A Wadden; Timothy S Bailey; Liana K Billings; Melanie Davies; Juan P Frias; Anna Koroleva; Ildiko Lingvay; Patrick M O'Neil; Domenica M Rubino; Dorthe Skovgaard; Signe O R Wallenstein; W Timothy Garvey
Journal:  JAMA       Date:  2021-04-13       Impact factor: 56.272

6.  Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Authors:  Domenica Rubino; Niclas Abrahamsson; Melanie Davies; Dan Hesse; Frank L Greenway; Camilla Jensen; Ildiko Lingvay; Ofri Mosenzon; Julio Rosenstock; Miguel A Rubio; Gottfried Rudofsky; Sayeh Tadayon; Thomas A Wadden; Dror Dicker
Journal:  JAMA       Date:  2021-04-13       Impact factor: 56.272

7.  Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Authors:  John P H Wilding; Rachel L Batterham; Salvatore Calanna; Melanie Davies; Luc F Van Gaal; Ildiko Lingvay; Barbara M McGowan; Julio Rosenstock; Marie T D Tran; Thomas A Wadden; Sean Wharton; Koutaro Yokote; Niels Zeuthen; Robert F Kushner
Journal:  N Engl J Med       Date:  2021-02-10       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.